JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose–Response Network Meta‐Analysis of Efficacy and Safety
JGH Open · 2026-03 · 10 (3)
DOI: 10.1002/jgh3.70388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JGH Open, online erschienen am 13.03.2026. Verfasst von Fares A Qtaishat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine University of Jordan Amman Jordan. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Crohn's disease has limited effective treatments, and direct comparative data for Janus kinase (JAK) inhibitors are scarce. We conducted a dose‐dependent network meta‐analysis of randomized controlled trials in adults, searching PubMed, Cochrane Library, Scopus, and Web of Science through February 17, 2025. A Bayesian dose–response model (Emax) was implemented with the MBNMA package in R, estimating risk ratios (RRs) with 95% credible intervals, and risk of bias was assessed with RoB 2. Nine trials ( n = 4838) evaluated upadacitinib, tofacitinib, and filgotinib across multiple doses. Upadacitinib 45 mg once daily achieved the greatest improvement in CDAI remission versus placebo (RR 1.8, 95% CrI 1.1–3.0). SUCRA rankings placed upadacitinib highest for overall clinical remission, CDAI mean change, and CDAI remission. Meta‐regression showed higher doses were associated with higher remission rates ( p = 0.041). Dose–response parameters indicated upadacitinib had a higher Emax and lower ED50 than comparators, suggesting greater efficacy and potency. Serious adverse events were more frequent with JAK inhibitors versus placebo (RR 1.61, 95% CI 1.15–2.25; p = 0.0082), with increases in sepsis, cardiovascular events, and elevated liver enzymes ( p < 0.05). Adverse event risk differed by agent ( p = 0.0008); upadacitinib increased overall adverse events versus placebo (RR 1.19, 95% CI 1.07–1.33) and serious infections (RR 5.39, 95% CI 2.98–9.74). JAK inhibitors improve clinical outcomes in Crohn's disease, with upadacitinib showing the most consistent efficacy, but safety risks warrant careful monitoring and head‐to‐head, long‐term studies.
Autor:innen und Institutionen
- Faculty of Medicine University of Jordan Amman Jordan.
- Faculty of Medicine Medipol University Istanbul Turkey.
- College of Literature, Science, and the Arts University of Michigan Ann Arbor USA.
- Department of Biology The American University in Cairo Cairo Egypt.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine The University of Jordan Amman Jordan.
ORCID-Profile: Adham Musa, Yousef A Ateiwi
Zitieren
APA
Qtaishat, F. A., AlKayyat, A., Yasin, J. A., A Tamimi, M. A., Tarawneh, J., AlDaher, L., Abdallah, S., Alghaniem, M. M. A., Abunamoos, A., Musa, A., Ateiwi, Y. A., Taha, Y., & Tamimi, T. A. (2026). JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose–Response Network Meta‐Analysis of Efficacy and Safety. JGH Open, 10(3). https://doi.org/10.1002/jgh3.70388
Vancouver
Qtaishat FA, AlKayyat A, Yasin JA, A Tamimi MA, Tarawneh J, AlDaher L, et al. JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose–Response Network Meta‐Analysis of Efficacy and Safety. JGH Open. 2026;10(3). doi:10.1002/jgh3.70388
BibTeX
@article{Qtaishat2026,
author = {Qtaishat, Fares A and AlKayyat, Ahmad and Yasin, Jehad A and A Tamimi, Mohammad-Amer and Tarawneh, Jana and AlDaher, Layan and Abdallah, Sarah and Alghaniem, Mohammad Moayad Ahmad and Abunamoos, Abdallah and Musa, Adham and Ateiwi, Yousef A and Taha, Yousef and Tamimi, Tarek A},
title = {JAK Inhibitors for Crohn's Disease: A Systematic Review and Dose–Response Network Meta‐Analysis of Efficacy and Safety},
journal = {JGH Open},
year = {2026},
volume = {10},
number = {3},
doi = {10.1002/jgh3.70388}
}
EUVIMED